📊 GOSS Key Takeaways
Is GOSS a Good Investment? Thesis Analysis
Gossamer Bio faces severe financial distress with negative stockholders' equity of -$122.8M, indicating liabilities exceed total assets by this amount. The company burns cash operationally at -$171.3M with only $37.7M cash reserves, providing less than 3 months of runway, while revenue has collapsed 57.7% YoY signaling fundamental business failure.
Fundamentals show steep revenue contraction, persistently large operating losses, and negative stockholders’ equity, resulting in extremely weak margins and ROA. While the current ratio is acceptable and there is no long‑term debt, cash is small relative to the annual operating cash burn, implying urgent financing needs and elevated dilution/distress risk.
Why Buy GOSS? Key Strengths
- Current ratio of 2.64x provides short-term liquidity coverage for immediate obligations
- Absence of long-term debt eliminates interest burden and refinancing risk
- Retains $37.7M in cash providing temporary operational runway
- No long-term debt reduces fixed obligations
- Current ratio of 2.64x provides short-term liquidity cushion
- Asset-light model with minimal capex requirements
GOSS Investment Risks to Consider
- Negative stockholders' equity of -$122.8M indicates technical insolvency with liabilities exceeding assets
- Operating cash burn of -$171.3M vastly exceeds cash reserves with estimated 2-3 month runway remaining
- Revenue collapsed 57.7% YoY reflecting severe commercialization or product failure in pharmaceutical operations
- Operating margin of -352.2% demonstrates core business is fundamentally unprofitable and unsustainable
- Liabilities of $295.0M exceed total assets of $172.2M by 71%, creating acute solvency crisis
- Negative equity with sustained heavy losses and -353% FCF margin
- Revenue down 57.7% YoY, indicating weak/volatile demand or one-time revenues
- High cash burn versus $37.7M cash suggests imminent funding/dilution risk
Key Metrics to Watch
- Quarterly cash burn rate and months of runway remaining
- Revenue trends for stabilization or further deterioration
- Ability to secure emergency financing or strategic alternatives
- Cash runway (cash & equivalents vs operating cash outflow)
- Revenue trend and recurrence from collaborations/products
GOSS Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.64x current ratio provides a solid financial cushion.
GOSS Profitability Ratios
GOSS vs Healthcare Sector
How Gossamer Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GOSS Overvalued or Undervalued?
Based on fundamental analysis, Gossamer Bio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GOSS Balance Sheet & Liquidity
GOSS 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Gossamer Bio, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.18 indicates the company is currently unprofitable.
GOSS Growth Metrics (YoY)
GOSS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $9.5M | -$23.5M | $-0.10 |
| Q2 2025 | $11.5M | $7.3M | $0.03 |
| Q1 2025 | N/A | -$36.6M | $-0.16 |
| Q3 2024 | N/A | -$23.5M | $-0.10 |
| Q2 2024 | N/A | $7.3M | $0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GOSS Capital Allocation
GOSS SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Gossamer Bio, Inc. (CIK: 0001728117)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GOSS
What is the AI rating for GOSS?
Gossamer Bio, Inc. (GOSS) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GOSS's key strengths?
Claude: Current ratio of 2.64x provides short-term liquidity coverage for immediate obligations. Absence of long-term debt eliminates interest burden and refinancing risk. ChatGPT: No long-term debt reduces fixed obligations. Current ratio of 2.64x provides short-term liquidity cushion.
What are the risks of investing in GOSS?
Claude: Negative stockholders' equity of -$122.8M indicates technical insolvency with liabilities exceeding assets. Operating cash burn of -$171.3M vastly exceeds cash reserves with estimated 2-3 month runway remaining. ChatGPT: Negative equity with sustained heavy losses and -353% FCF margin. Revenue down 57.7% YoY, indicating weak/volatile demand or one-time revenues.
What is GOSS's revenue and growth?
Gossamer Bio, Inc. reported revenue of $48.5M.
Does GOSS pay dividends?
Gossamer Bio, Inc. does not currently pay dividends.
Where can I find GOSS SEC filings?
Official SEC filings for Gossamer Bio, Inc. (CIK: 0001728117) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GOSS's EPS?
Gossamer Bio, Inc. has a diluted EPS of $-0.75.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GOSS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Gossamer Bio, Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GOSS stock overvalued or undervalued?
Valuation metrics for GOSS: ROE of N/A (sector avg: 15%), net margin of -351.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GOSS stock in 2026?
Our dual AI analysis gives Gossamer Bio, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GOSS's free cash flow?
Gossamer Bio, Inc.'s operating cash flow is $-171.3M, with capital expenditures of $79.0K. FCF margin is -353.5%.
How does GOSS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -351.5% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.64 (avg: 2).